⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25520926 | 1.00 | — | — | |
| SCHEMBL22239042 | 0.83 | TSHR (0.44) | — | |
| SCHEMBL28286227 | 0.79 | — | — | |
| SCHEMBL13265351 | 0.79 | — | — | |
| SCHEMBL21016546 | 0.75 | — | — | |
| SCHEMBL23499062 | 0.75 | — | — | |
| SCHEMBL23498910 | 0.75 | — | — | |
| SCHEMBL24104407 | 0.75 | — | — | |
| SCHEMBL16844771 | 0.75 | — | — | |
| SCHEMBL19594952 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423069-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-12071411-B2 | Inhibitors of HIF-2α and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-118176183-A | HIF-2 alpha inhibitors and methods of use thereof | 艾库斯生物科学有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-116478129-A | Quinoline compound and use thereof | 深圳默元生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116490201-A | Inhibitors of YAP/TAZ-TEAD tumor proteins, their synthesis and use | 布里奇恩生物科学公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023077046-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023284719-A1 | A PT CONJUGATE AND THE USE THEREOF | NANJING UNIVERSITY (CN) | 2023-01-19 | — | — | WO | disclosed |
| CN-110041333-B | Bromodomain inhibitor compounds and uses thereof | 中国科学院上海药物研究所 | 2022-03-01 | — | — | CN | disclosed |
| CN-113543852-A | Pyrrolopyrazole derivatives | 第一三共株式会社 | 2021-10-22 | — | — | CN | disclosed |
| WO-2019141131-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2019-07-25 | — | — | WO | disclosed |
| EP-3172211-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-05-31 | — | — | EP | disclosed |
| EP-2692827-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2016-03-23 | — | — | EP | disclosed |
| WO-2016011930-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-01-28 | — | — | WO | disclosed |
| EP-2692827-A2 | Liquid-crystalline medium | Merck Patent GmbH (DE) | 2014-02-05 | — | — | EP | disclosed |
| WO-2013018929-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-07 | — | — | WO | disclosed |
| WO-2011076329-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2011-06-30 | — | — | WO | disclosed |
| EP-2144975-B1 | LIQUID- CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2010-10-27 | — | — | EP | disclosed |
| EP-1808473-B1 | Liquid crystal medium | MERCK PATENT GMBH (DE) | 2010-02-10 | — | — | EP | disclosed |
| EP-1365001-B1 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |